Sanara Medtech Share Price (NASDAQ: SMTI)

$33.7

▲

-0.03

(-0.09%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Sanara Medtech Stock chart to analyse performance

Sanara Medtech stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$33.40
Today's High:$33.70
$33.70
0.89%
Downside
Day's Volatility :0.89%
Upside
0.0%
52 Weeks Low:$23.53
52 Weeks High:$39.08
$33.70
30.18%
Downside
52 Weeks Volatility :39.79%
Upside
13.77%

Sanara Medtech Stock Returns

Period	Sanara Medtech Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	14.82%	3.6%	0.0%
6 Months	1.77%	-7.7%	0.0%
1 Year	-3.13%	-12.6%	0.0%
3 Years	1.21%	10.2%	-4.1%

Sanara Medtech Inc Key Stats

Check Sanara Medtech key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$33.73
Open	$33.4
Today's High	$33.7
Today's Low	$33.4
Market Capitalization	$302.1M
Today's Volume	$17.2K
52 Week High	$39.08
52 Week Low	$23.53
Revenue TTM	$97.2M
EBITDA	$996.4K
Earnings Per Share (EPS)	$-1.16
Profit Margin	-10.22%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-26.38%

Stock Returns calculator for Sanara Medtech Stock including INR - Dollar returns

The Sanara Medtech stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Sanara Medtech investment value today

Current value as on today

₹1,03,022

Returns

₹3,022

(+3.02%)

Returns from Sanara Medtech Stock

₹2,262 (-2.26%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Sanara Medtech Stock

-7%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Sanara Medtech Stock from India on INDmoney has decreased by -7% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Sanara Medtech Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
2.37%
Vanguard Group Inc
1.98%
Geode Capital Management, LLC
1.00%
Marshall Wace Asset Management Ltd
0.80%
State Street Corp
0.71%
Northern Trust Corp
0.46%

Analyst Recommendation on Sanara Medtech Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Sanara Medtech(by analysts ranked 0 to 5 stars)

Sanara Medtech Share Price Target

What analysts predicted

Upside of 48.37%

Target:

$50.00

Current:

$33.70

Sanara Medtech share price target is $50.00, a slight Upside of 48.37% compared to current price of $33.70 as per analysts' prediction.

Sanara Medtech Stock Insights

Price Movement
In the last 1 month, SMTI stock has moved up by 38.2%
Increasing Revenue
Revenue is up for the last 2 quarters, 23.43M → 25.83M (in $), with an average increase of 9.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -3.52M → -2.01M (in $), with an average increase of 75.1% per quarter
SMTI vs RMD (1 yr)
In the last 1 year, Resmed Inc. has given 12.2% return, outperforming this stock by 19.1%
SMTI vs ISRG (3 yr)
In the last 3 years, Intuitive Surgical, Inc. has given 25.0% return, outperforming this stock by 27.5%
Price to Sales
ForSMTI every $1 of sales, investors are willing to pay $2.9, whereas for Resmed Inc., the investors are paying $7.8 for every $1 of sales.

Sanara Medtech Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$11.8M	↑ 101.56%
Net Income	$-2.8M	↑ 372.18%
Net Profit Margin	-24.1%	↓ 13.81%

	FY20	Y/Y Change
Revenue	$15.6M	↑ 32.47%
Net Income	$-4.4M	↑ 53.62%
Net Profit Margin	-27.95%	↓ 3.85%

	FY21	Y/Y Change
Revenue	$24.1M	↑ 54.9%
Net Income	$-7.9M	↑ 81.84%
Net Profit Margin	-32.81%	↓ 4.86%

	FY22	Y/Y Change
Revenue	$45.8M	↑ 89.87%
Net Income	$-7.9M	↑ 0.2%
Net Profit Margin	-17.31%	↑ 15.5%

	FY23	Y/Y Change
Revenue	$65.0M	↑ 41.77%
Net Income	$-4.3M	↓ 45.79%
Net Profit Margin	-6.62%	↑ 10.69%

	FY24	Y/Y Change
Revenue	$86.7M	↑ 33.36%
Net Income	$-9.7M	↑ 124.59%
Net Profit Margin	-11.15%	↓ 4.53%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$18.5M	↑ 4.79%
Net Income	$-1.8M	↑ 643.77%
Net Profit Margin	-9.52%	↓ 8.18%

	Q2 FY24	Q/Q Change
Revenue	$20.2M	↑ 8.75%
Net Income	$-3.5M	↑ 98.62%
Net Profit Margin	-17.38%	↓ 7.86%

	Q3 FY24	Q/Q Change
Revenue	$21.7M	↑ 7.5%
Net Income	$-2.9M	↓ 18.44%
Net Profit Margin	-13.19%	↑ 4.19%

	Q4 FY24	Q/Q Change
Revenue	$26.3M	↑ 21.38%
Net Income	$-1.5M	↓ 46.16%
Net Profit Margin	-5.85%	↑ 7.34%

	Q1 FY25	Q/Q Change
Revenue	$23.4M	↓ 10.92%
Net Income	$-3.5M	↑ 129.25%
Net Profit Margin	-15.05%	↓ 9.2%

	Q2 FY25	Q/Q Change
Revenue	$25.8M	↑ 10.23%
Net Income	$-2.0M	↓ 42.89%
Net Profit Margin	-7.8%	↑ 7.25%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$10.6M	↑ 98.06%

	FY20	Y/Y Change
Profit	$14.0M	↑ 32.33%

	FY21	Y/Y Change
Profit	$21.8M	↑ 56.28%

	FY22	Y/Y Change
Profit	$39.5M	↑ 80.84%

	FY23	Y/Y Change
Profit	$57.1M	↑ 44.72%

	FY24	Y/Y Change
Profit	$78.5M	↑ 37.45%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$15.5M	↑ 4.96%

	Q2 FY24	Q/Q Change
Profit	$18.2M	↑ 16.79%

	Q3 FY24	Q/Q Change
Profit	$19.7M	↑ 8.43%

	Q4 FY24	Q/Q Change
Profit	$24.1M	↑ 22.24%

	Q1 FY25	Q/Q Change
Profit	$21.6M	↓ 10.21%

	Q2 FY25	Q/Q Change
Profit	$22.8M	↑ 5.46%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-2.2M	↓ 882.05%
Investing Cash Flow	$-1.2M	↑ 14013.38%
Financing Cash Flow	$9.8M	↓ 4809.23%

	FY20	Y/Y Change
Operating Cash Flow	$-4.0M	↑ 86.15%
Investing Cash Flow	$-2.7M	↑ 129.25%
Financing Cash Flow	$622.3K	↓ 93.65%

	FY21	Y/Y Change
Operating Cash Flow	$-4.8M	↑ 19.33%
Investing Cash Flow	$-5.3M	↑ 92.57%
Financing Cash Flow	$28.3M	↑ 4446.9%

	FY22	Y/Y Change
Operating Cash Flow	$-5.6M	↑ 15.38%
Investing Cash Flow	$-3.5M	↓ 33.55%
Financing Cash Flow	$-627.3K	↓ 102.22%

	FY23	Y/Y Change
Operating Cash Flow	$-3.2M	↓ 41.57%
Investing Cash Flow	$-10.2M	↑ 190.67%
Financing Cash Flow	$9.6M	↓ 1636.81%

	FY24	Y/Y Change
Operating Cash Flow	$-23.8K	↓ 99.27%
Investing Cash Flow	$-6.6M	↓ 35.23%
Financing Cash Flow	$17.4M	↑ 80.13%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-1.6M	↑ 87.9%
Investing Cash Flow	$-65.8K	↑ 21.27%
Financing Cash Flow	$-658.8K	↑ 254.4%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-1.4M	↓ 11.44%
Investing Cash Flow	$-58.8K	↓ 10.72%
Financing Cash Flow	$4.8M	↓ 827.52%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$2.1M	↓ 245.22%
Investing Cash Flow	$-6.4M	↑ 10718.33%
Financing Cash Flow	$14.4M	↑ 201.15%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$932.0K	↓ 54.54%
Investing Cash Flow	$-130.0K	↓ 97.96%
Financing Cash Flow	$-1.2M	↓ 108.32%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-2.0M	↓ 314.46%
Investing Cash Flow	$-5.2M	↑ 3884.69%
Financing Cash Flow	$12.0M	↓ 1098.23%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$2.7M	↓ 233.27%
Investing Cash Flow	$-3.9M	↓ 24.17%
Financing Cash Flow	$-2.5M	↓ 120.56%

Sanara Medtech Technicals Summary

Sell

Neutral

Buy

Sanara Medtech is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Sanara Medtech Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Sanara Medtech Inc	38.25%	1.77%	-3.13%	1.21%	-11.5%
Intuitive Surgical, Inc.	-2.14%	-16.61%	-2.2%	129.39%	91.27%
Alcon Ag	-9.17%	-15.22%	-16.6%	20.12%	40.07%
West Pharmaceutical Services Inc	3.24%	8.32%	-18.78%	-16.58%	-12.33%
Resmed Inc.	-1.56%	17.91%	12.23%	25.22%	53.62%
Becton, Dickinson And Company	9.36%	-15.57%	-20.36%	-24.43%	-19.91%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Sanara Medtech Inc	NA	NA	NA	-0.98	-0.26	-0.02	NA	3.98
Intuitive Surgical, Inc.	66.27	66.27	3.47	8.14	0.16	0.09	NA	49.79
Alcon Ag	36.78	36.78	2.16	3.1	0.05	0.03	0.0	44.73
West Pharmaceutical Services Inc	36.74	36.74	3.55	6.76	0.18	0.11	0.0	40.74
Resmed Inc.	28.99	28.99	1.9	9.5	0.26	0.14	0.01	40.77
Becton, Dickinson And Company	35.34	35.34	0.96	14.37	0.06	0.04	0.02	88.87

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Sanara Medtech Inc	Buy	$302.1M	-11.5%	NA	-10.22%
Intuitive Surgical, Inc.	Buy	$169.9B	91.27%	66.27	28.51%
Alcon Ag	Buy	$39.3B	40.07%	36.78	10.7%
West Pharmaceutical Services Inc	Buy	$17.7B	-12.33%	36.74	16.48%
Resmed Inc.	Buy	$40.3B	53.62%	28.99	27.22%
Becton, Dickinson And Company	Buy	$55.3B	-19.91%	35.34	7.41%

About Sanara Medtech Inc

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Organization	Sanara Medtech
Employees	141
CEO	Mr. Ronald T. Nixon
Industry	Pharmaceuticals: Generic

Key Management of Sanara Medtech Inc

Name	Title
Mr. Ronald T. Nixon	Executive Chairman & CEO
Mr. Jacob A. Waldrop	Chief Operating Officer
Ms. Elizabeth B. Taylor	Chief Financial Officer
Mr. Bill Fitzgerald	Chief Compliance Officer
Ms. Tricia Matteson	Vice President of Marketing
Mr. Tyler Palmer	Chief Corporate Development & Strategy Officer
Dr. Christopher A. Morrison FACHM, FAPWCA, FCCWS, M.D.	President of Telehealth Services
Mr. Seth Yon	President of Commercial
Ms. Nina Bionda	Chief R&D Officer
Mr. Callon Nichols	Vice President of Corporate Operations

Important FAQs about investing in SMTI Stock from India :

What is Sanara Medtech share price today?

Sanara Medtech share price today is $33.70 as on August 30, 2025 at 1:29 am IST at the close of the market. Sanara Medtech share today touched a day high of $33.70 and a low of $33.40.

What is the 52 week high and 52 week low for Sanara Medtech share?

Sanara Medtech share touched a 52 week high of $39.08 and a 52 week low of $23.53. Sanara Medtech stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $33.70, lower by 13.77% versus the 52 week high.

How to invest in Sanara Medtech Stock (SMTI) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Sanara Medtech on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sanara Medtech Shares that will get you 0.0445 shares as per Sanara Medtech share price of $33.70 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Sanara Medtech Stock (SMTI) from India?

Indian investors can start investing in Sanara Medtech (SMTI) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Sanara Medtech stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Sanara Medtech share’s latest price of $33.70 as on August 30, 2025 at 1:29 am IST, you will get 0.2967 shares of Sanara Medtech. Learn more about fractional shares .

What are the returns that Sanara Medtech has given to Indian investors in the last 5 years?

Sanara Medtech stock has given -11.5% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?